71.83
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $71.83, with a volume of 7.65M.
It is down -1.14% in the last 24 hours and up +2.83% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$72.66
Open:
$72.725
24h Volume:
7.65M
Relative Volume:
1.69
Market Cap:
$222.77B
Revenue:
$54.98B
Net Income/Loss:
$7.77B
P/E Ratio:
28.85
EPS:
2.49
Net Cash Flow:
$9.14B
1W Performance:
+4.53%
1M Performance:
+2.83%
6M Performance:
+3.22%
1Y Performance:
-8.06%
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
AZN
Astrazeneca PLC
|
71.83 | 225.28B | 54.98B | 7.77B | 9.14B | 2.49 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
Feb-13-25 | Upgrade | UBS | Neutral → Buy |
Feb-12-25 | Initiated | Morgan Stanley | Overweight |
Nov-20-24 | Upgrade | UBS | Sell → Neutral |
Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
May-30-24 | Initiated | Goldman | Buy |
Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
Jan-23-24 | Initiated | Morgan Stanley | Overweight |
Jan-16-24 | Resumed | UBS | Sell |
Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
Dec-18-23 | Initiated | HSBC Securities | Buy |
Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Jul-12-23 | Upgrade | UBS | Neutral → Buy |
Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Aug-29-22 | Upgrade | Argus | Hold → Buy |
Jun-14-22 | Downgrade | UBS | Buy → Neutral |
Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
Aug-12-21 | Resumed | JP Morgan | Overweight |
Apr-12-21 | Downgrade | Argus | Buy → Hold |
Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
Feb-25-21 | Upgrade | UBS | Neutral → Buy |
Jan-15-21 | Initiated | Deutsche Bank | Buy |
Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Nov-30-20 | Upgrade | UBS | Sell → Neutral |
Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
Sep-29-20 | Initiated | Berenberg | Buy |
Nov-22-19 | Initiated | SVB Leerink | Outperform |
Oct-25-19 | Upgrade | Liberum | Hold → Buy |
Apr-02-19 | Downgrade | UBS | Neutral → Sell |
Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
Dec-11-18 | Resumed | Jefferies | Hold |
Oct-09-18 | Initiated | Guggenheim | Buy |
Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
Feb-05-18 | Reiterated | Bernstein | Outperform |
Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
Earnings Snapshot:AstraZeneca surpasses Q2 estimates;reaffirms FY outl - Seeking Alpha
FTSE 100 rises on lift from AstraZeneca results - MarketScreener
AstraZeneca's profit, revenue lifted by cancer drugs - The Edge Malaysia
FTSE 100 Live: Mixed start to trading, Games Workshop impresses, AstraZeneca and Barclays less so - Proactive Investors
AstraZeneca beats forecasts after record US growth - Financial Times
AstraZeneca maintains outlook as pipeline delivers strong late-stage results - Proactive Investors
Astrazeneca: Demand for cancer drugs boosts pharmaceutical giant - Yahoo.co
FTSE 100 Live: London stocks set to rebound as AstraZeneca, Barclays, Entain report By Proactive Investors - Investing.com UK
Shareholders of AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights – AZN - ACCESS Newswire
FTSE 100 Live: London stocks set to rebound as AstraZeneca, Barclays, Entain report - Proactive Investors
AstraZeneca Profit, Revenue Lifted by Cancer Drugs - Bloomberg
AstraZeneca (AZN) Bets Big on U.S. with $50 Billion Manufacturing Expansion - MSN
AstraZeneca beats second-quarter profit expectations, maintains outlook - Reuters
AstraZeneca beats second-quarter profit expectations - MarketScreener
AstraZeneca beats profit expectations on robust drug sales, U.S. demand - Yahoo.co
AstraZeneca PLC (AZN) Announced Positive Results for its Phase 3 Trial of Gefurulimab - Insider Monkey
AstraZeneca’s NIAGARA-2 Study: A New Frontier in Bladder Cancer Treatment - TipRanks
AstraZeneca’s ARTEMIDE-Lung02: A New Phase III Study in Lung Cancer Treatment - TipRanks
AstraZeneca’s Fasenra Study: Monitoring Real-World Safety and Effectiveness - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Tempus AI, Inc. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
AstraZeneca gets FDA priority review for Imfinzi application - Seeking Alpha
What makes AstraZeneca PLC Depositary Receipt stock price move sharplyDiscover undervalued stocks before they soar - jammulinksnews.com
Trending tickers: Palantir, Samsung, Heineken, Volkswagen and AstraZeneca - Yahoo.co
Here’s where the AstraZeneca share price could end the year - MSN
What is the dividend policy of AstraZeneca PLC Depositary Receipt stockDiscover high-impact stocks for growth - jammulinksnews.com
What institutional investors are buying AstraZeneca PLC Depositary Receipt stockBreakthrough financial growth - jammulinksnews.com
How does AstraZeneca PLC Depositary Receipt compare to its industry peersAchieve explosive financial results today - jammulinksnews.com
AstraZeneca’s (AZN) Dividend: Resilient, Predictable, and Built on Innovation - MSN
AstraZeneca’s Osimertinib Study: A Potential Game-Changer for NSCLC Treatment - The Globe and Mail
AstraZeneca’s New Trial: A Potential Game-Changer in Prostate Cancer Treatment - The Globe and Mail
AstraZeneca’s AZD4144 Study Completion: Key Insights for Investors - The Globe and Mail
AstraZeneca’s AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment - The Globe and Mail
AstraZeneca’s Latest Study: Evaluating Ceralasertib’s Impact on Cancer Drug Pharmacokinetics - The Globe and Mail
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Bristol Appoints AstraZeneca’s Massacesi As Next CMO - insights.citeline.com
What drives AstraZeneca PLC Depositary Receipt stock priceFree Stock Selection - PrintWeekIndia
AstraZeneca PLC Depositary Receipt Stock Analysis and ForecastFree Market Dynamics Reports - PrintWeekIndia
AstraZeneca (AZN) Sees Increased Bullish Option Activity - GuruFocus
AstraZeneca’s MAGELLAN Study: A New Horizon in NSCLC Treatment - The Globe and Mail
AstraZeneca’s Promising Phase 2 Study on Trastuzumab Deruxtecan for HER2 Tumors - The Globe and Mail
AstraZeneca and Amgen’s Phase III COPD Study: Market Implications - TipRanks
Eli Lilly and AstraZeneca’s Promising Phase 3 Study on KRAS G12C-Mutant NSCLC - TipRanks
AstraZeneca’s NT-175 Study: A New Frontier in Cancer Treatment - TipRanks
AstraZeneca’s Latest Study on Acalabrutinib: A Potential Game Changer for CLL Patients with Heart Conditions - TipRanks
AstraZeneca’s eVOLVE-02 Study: A New Frontier in Cancer Treatment - TipRanks
AstraZeneca’s Phase III Study on AZD0780: A Potential Game-Changer for Cholesterol Management - TipRanks
AstraZeneca’s ASTER Study: Real-World Insights into Anifrolumab for SLE - TipRanks
AstraZeneca’s Phase 3 Trial: A New Hope for Advanced Biliary Tract Cancer Treatment - The Globe and Mail
AstraZeneca’s ARTEMIDE-Lung04 Study: A New Hope for mNSCLC Treatment? - The Globe and Mail
AstraZeneca’s RACE-2L Study: Real-World Insights into NSCLC Treatment - TipRanks
AstraZeneca’s PROVIDENCE Study: Advancing Breast Cancer Treatment with Real-World Insights - TipRanks
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):